Profile data is unavailable for this security.
About the company
Ocumension Therapeutics is a China-based holding company principally involved in the discovering, developing and commercializing ophthalmic therapies. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The Company conducts its businesses in the domestic market.
- Revenue in HKD (TTM)265.97m
- Net income in HKD-410.01m
- Incorporated2018
- Employees444.00
- LocationOcumension TherapeuticsNo. 1858 Yinzhongnan RoadGuoxiang Subdistrict, Wuzhong DistrictSUZHOU KY1-1205ChinaCHN
- Websitehttps://www.ocumension.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cutia Therapeutics | 148.57m | -2.12bn | 2.34bn | 298.00 | -- | 1.61 | -- | 15.76 | -6.97 | -6.97 | 0.4887 | 4.79 | -- | -- | -- | 498,571.20 | -- | -- | -- | -- | 51.60 | -- | -1,426.91 | -- | 5.38 | -- | 0.153 | -- | 1,110.83 | -- | -253.30 | -- | -- | -- |
| Jiangsu Recbio Technology Co Ltd | 0.00 | -617.47m | 4.34bn | 472.00 | -- | 3.72 | -- | -- | -1.28 | -1.28 | 0.00 | 2.41 | 0.00 | -- | -- | 0.00 | -25.47 | -- | -30.68 | -- | -- | -- | -- | -- | 2.33 | -- | 0.378 | -- | -- | -- | 20.86 | -- | -- | -- |
| Shandong Boan Biotechnology Co Ltd | 667.32m | -128.88m | 4.59bn | 813.00 | -- | 3.22 | -- | 6.88 | -0.2531 | -0.2531 | 1.31 | 2.80 | 0.2732 | 1.35 | 2.53 | 820,806.90 | -5.28 | -- | -7.02 | -- | 66.16 | -- | -19.31 | -- | 0.8383 | -7.47 | 0.2491 | -- | 19.80 | -- | 64.02 | -- | -- | -- |
| Ocumension Therapeutics | 265.97m | -410.01m | 4.68bn | 444.00 | -- | 1.48 | -- | 17.60 | -0.6319 | -0.6319 | 0.4097 | 4.56 | 0.078 | 3.61 | 2.12 | 599,034.80 | -12.03 | -38.78 | -13.21 | -41.47 | 58.60 | 62.30 | -154.16 | -975.82 | 3.72 | -- | 0.0451 | -- | 54.99 | -- | 5.68 | -- | 319.66 | -- |
| Beijing Luzhu Biotechnology Co Ltd | 0.00 | -269.19m | 4.73bn | 133.00 | -- | 4.33 | -- | -- | -1.35 | -1.35 | 0.00 | 5.44 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | 6.41 | -- | 0.0185 | -- | -- | -- | 65.62 | -- | -- | -- |
| Consun Pharmaceutical Group Ltd | 2.80bn | 846.96m | 4.81bn | 3.13k | 5.38 | 1.18 | 5.16 | 1.72 | 1.06 | 1.06 | 3.50 | 4.83 | 0.4981 | 2.08 | 10.05 | 894,218.40 | 15.13 | 12.04 | 22.57 | 19.25 | 74.19 | 74.55 | 30.37 | 24.89 | 2.62 | -- | 0.1155 | 40.84 | 10.71 | 7.03 | 14.88 | 11.01 | -22.93 | 18.43 |
| Sihuan Pharmaceutical Holdings Group Ltd | 2.01bn | -58.32m | 4.85bn | 2.87k | -- | 1.01 | -- | 2.41 | -0.0063 | -0.0063 | 0.216 | 0.5128 | 0.1572 | 0.8101 | 4.72 | 699,369.60 | -2.18 | -6.85 | -3.34 | -9.10 | 69.64 | 75.81 | -13.85 | -36.23 | 1.35 | -2.63 | 0.1863 | -- | -14.70 | -8.60 | 97.23 | -- | 0.9325 | -- |
| Shanghai Fudan-Zhangjiang Bio-Pharm. Co | 873.63m | 110.32m | 5.46bn | 948.00 | 16.32 | 0.712 | -- | 6.26 | 0.1072 | 0.1072 | 0.8296 | 2.46 | 0.2852 | 1.44 | 1.62 | 921,547.10 | 3.59 | 7.03 | 4.35 | 9.05 | 91.40 | 92.17 | 12.59 | 17.26 | 3.94 | 568.37 | 0.0062 | 39.16 | -17.50 | 2.78 | -21.28 | -0.6326 | 20.49 | -- |
| Everest Medicines Ltd | 135.95m | -911.66m | 6.11bn | 432.00 | -- | 1.12 | -- | 44.92 | -2.92 | -2.92 | 0.4343 | 16.80 | 0.0203 | 2.25 | 4.57 | 314,705.80 | -13.63 | -30.52 | -15.06 | -33.14 | 72.67 | -- | -670.57 | -5,745.25 | 8.29 | -- | 0.0979 | -- | 884.46 | -- | -241.50 | -- | 4.65 | -- |
| China Shineway Pharmaceutical Group Ltd | 4.88bn | 1.05bn | 6.59bn | 3.44k | 5.75 | 0.8679 | 5.38 | 1.35 | 1.39 | 1.39 | 6.45 | 9.18 | 0.5073 | 1.44 | 6.31 | 1,419,074.00 | 10.89 | 8.03 | 14.15 | 9.77 | 75.15 | 74.55 | 21.47 | 17.87 | 2.98 | -- | 0.0411 | 36.29 | 14.32 | 11.94 | 34.14 | 13.89 | 0.6396 | 12.88 |
| Tong Ren Tang Technologies Co Ltd | 7.31bn | 637.15m | 6.63bn | 4.10k | 10.41 | 0.892 | 4.85 | 0.9073 | 0.4975 | 0.4975 | 5.71 | 5.81 | 0.5212 | 0.9835 | 5.68 | 1,783,091.00 | 7.64 | 7.68 | 12.10 | 12.32 | 42.04 | 43.50 | 14.65 | 16.11 | 2.37 | -- | 0.1443 | 39.94 | 13.04 | 6.01 | 1.25 | -2.73 | -22.26 | -0.0089 |
Data as of Jul 26 2024. Currency figures normalised to Ocumension Therapeutics's reporting currency: Hong Kong Dollar HKD
14.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Temasek Holdings Pte Ltd. (Investment Management)as of 15 Jul 2024 | 41.44m | 5.97% |
| Capital Research & Management Co. (World Investors)as of 06 Dec 2023 | 34.37m | 4.95% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 9.36m | 1.35% |
| Zhong Geng Fund Management Co. , Ltd.as of 31 Dec 2023 | 3.13m | 0.45% |
| Capital Research & Management Co. (Global Investors)as of 30 Jun 2024 | 3.10m | 0.45% |
| FIL Investment Management (Hong Kong) Ltd.as of 31 May 2024 | 2.60m | 0.38% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2022 | 2.36m | 0.34% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 2.14m | 0.31% |
| UBS Asset Management (Hong Kong) Ltd.as of 28 Mar 2024 | 2.04m | 0.29% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 1.92m | 0.28% |
More ▼
Data from 31 Dec 2023 - 24 Jul 2024Source: FactSet Research Systems Inc.
